Developer docs
API playgroundTry for free, no card

Search company profiles

ProQinase

Full company profile

uuid002hiil

Namestring
ProQinase
Legal namestring
Reaction Biology
Websiteurl
proqinase.com
Company typeenum
Private
Founded yearint
2001
Descriptiontext

ProQinase is a contract research organization (CRO) specializing in preclinical drug discovery services with a primary focus on kinase profiling and epigenetic target screening. Founded in 2001 and headquartered in Freiburg, Germany, the company operates under the Reaction Biology legal entity with facilities in the European Union and the United States. Its service portfolio spans biochemical assays (kinase panels, methyltransferase, HDAC, HAT, demethylase, GPCR, ion channel, phosphatase), cell-based assays (ProLiFiler cancer cell panel, 3D tumor spheroids, immune checkpoint, CAR-T), biophysical assays (SPR, MST, ITC, TSA), in vivo pharmacology (xenograft, orthotopic, PK/PD), safety/toxicology, GMP bioassays, and custom assay development. Proprietary platforms include LinkLight (protein-protein interaction analysis), ProLiFiler (cancer cell panel screening), and SubQperior (tumor models), supported by a library of hundreds of validated proteins and over 1,000 cell lines.

The company serves pharmaceutical companies, biotechnology firms, and academic research institutions, with named relationships including Boehringer-Ingelheim, Perha Pharmaceuticals, ManRos Therapeutics, the University of North Carolina at Chapel Hill, and Ludwig-Maximilian's University of Munich. Revenue is generated primarily through project-based contract research services and the sale of recombinant kinase proteins and assay reagents, with pricing structured on a quote-per-project basis typical of enterprise CRO engagements. Recent product expansion covers emerging modalities including Antibody Drug Conjugates, RAS drug discovery, Targeted Protein Degradation, and EGFR programs, alongside an immuno-oncology service line and entry into the Chinese market via a localized website. Leadership is provided by CEO Sebastian Dempe and founder Christoph Schächtele, who has been involved since the company's inception.

Short descriptiontext

ProQinase is a Germany-based preclinical drug discovery CRO operating under Reaction Biology, providing kinase profiling, epigenetic, cell-based, biophysical, and in vivo pharmacology services to pharmaceutical, biotech, and academic clients across US and EU facilities.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersFreiburg, Germany
HQ citystring
Freiburg
HQ countrystring
Germany
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
preclinical drug discovery, kinase assay services, contract research organization, recombinant kinase proteins, epigenetic drug discovery
Industry4 codes
PRIMARYHLAGAAAB
Preclinical CROs (Discovery/Pharmacology/DMPK)
SECONDARYHLAGAAAD
Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity)
SECONDARYHLAGAFAC
DMPK / ADME & Bioanalysis
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Preclinical Drug Discovery Services
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Contract Research Services
TypeProfessional Services
Description

CRO services providing preclinical drug discovery including biochemical assays, cell-based assays, biophysical assays, safety & toxicology, in vivo pharmacology, and custom assay development for pharmaceutical, biotech, and academic clients

reactionbiology.com
2Recombinant Protein Products
TypeHardware Sales
Description

Sale of kinase proteins, epigenetic proteins, and related assay reagents including active protein kinases, lipid kinases, methyltransferase proteins, deacetylase proteins, and assay kits

reactionbiology.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales
Pricing details1 tier
1Custom CRO project-based pricing
ModelOtherBilling cadenceMulti-year contract
Notes

Contract research services are quoted on a project-by-project basis depending on assay complexity, number of targets, and project scope

reactionbiology.com
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

ProQinase, operating as the kinase services brand of Reaction Biology, is a contract research organization (CRO) providing preclinical drug discovery services. Core offerings include kinase panel screening, biochemical and cell-based assays, biophysical assays (SPR, MST, ITC, TSA), in vivo pharmacology, immuno-oncology platforms, recombinant kinase proteins, and safety/toxicology testing for pharmaceutical, biotech, and academic clients.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Therapies developed using company services have received regulatory approval from FDA and other global regulatory agencies
Product overview1 text field

ProQinase (now part of Reaction Biology) offers an integrated drug discovery service portfolio. The core offerings include kinase panel screening services and recombinant kinase products (Active Protein Kinases, Active Lipid Kinases), supplemented by epigenetic assay services (Methyltransferase, Demethylase, HDAC, HAT, Reader Domain assays). The platform includes discovery tools (KinaseFinder, Kinase SubstrateFinder, Kinase Mapper, MoA Finder, Biomarker Analysis Tool) for target identification and compound profiling. Additional services span biophysical assays (SPR, MST, ITC, TSA), cell-based assays (ProLiFiler Cancer Cell Panel, 3D Tumor Spheroid), in vivo pharmacology models, immuno-oncology platforms (CAR-T), GMP bioassays, safety/toxicology screening, and custom drug discovery services. The product line also includes assay kits (BromoMELT Assay Kit) and reagent products. The company operates from strategically located facilities in the US and EU with over 1,000 cell lines and hundreds of validated protein targets.

Product and service14 records
1Kinase Panel Screening
CategoryBiochemical Assay Services
Description

Comprehensive screening of kinases across the kinome to identify target engagement and selectivity profiles for pharmaceutical, biotech, and academic clients.

2Kinase Assay Services
CategoryBiochemical Assay Services
Description

Individual kinase assay services providing quantitative measurement of kinase activity and inhibition for drug discovery clients.

3Epigenetic Assay Services
CategoryBiochemical Assay Services
Description

Biochemical assays for profiling methyltransferase, demethylase, histone acetyltransferase (HAT), histone deacetylase (HDAC), sirtuin, and reader domain activity for epigenetic drug discovery.

4Biophysical Assay Services
CategoryBiophysical Assay Services
Description

Biophysical assays including Surface Plasmon Resonance (SPR), Thermal Shift Assay (TSA), Microscale Thermophoresis (MST), and Isothermal Titration Calorimetry (ITC) for measuring molecular interactions and binding kinetics.

5ProLiFiler Cancer Cell Panel Screening
CategoryCell-Based Assay Services
Description

Proprietary cancer cell line panel screening service for phenotypic profiling of compound efficacy across a panel of cancer cell lines.

63D Tumor Spheroid Assay
CategoryCell-Based Assay Services
Description

Three-dimensional cell culture assay using tumor spheroids for physiologically relevant drug efficacy testing in oncology drug discovery.

7CAR-T Cell Therapy Platform
CategoryImmuno-Oncology Services
Description

Platform for evaluating CAR-T cell therapeutic candidates and immune responses in immuno-oncology drug discovery.

8In Vivo Pharmacology
CategoryIn Vivo Pharmacology Services
Description

Preclinical in vivo efficacy models including xenograft tumor models, PK/PD studies, and translational pharmacology for drug discovery programs.

9GMP Bioassays
CategoryGMP Testing Services
Description

Regulatory-compliant bioanalytical testing and quality control services for bioprocessing and biotherapeutic manufacturing.

10Safety & Toxicology Services
CategorySafety Assessment Services
Description

Comprehensive safety profiling including in vitro safety screening, cardiac safety assessment, cytochrome P450 assays, and GLP toxicology for drug development programs.

11Custom Drug Discovery Services
CategoryCustom Research Services
Description

Customized kinase and epigenetic drug discovery services tailored to specific client research needs, including custom assay development and cell line generation.

12Active Protein Kinases
CategoryRecombinant Protein Products
Description

Recombinant active protein kinases sold as standalone reagents for use in biochemical screening and profiling assays.

13Active Lipid Kinases
CategoryRecombinant Protein Products
Description

Recombinant lipid kinases sold as standalone reagents for lipid kinase inhibitor screening and research.

14BromoMELT Assay Kit
CategoryAssay Kit Products
Description

Assay kit for measuring bromodomain binding and ligand-induced thermal stability, sold as a standalone reagent product.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Recent move1 record

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Eurofins Scientific is the parent of Eurofins Discovery and DiscoverX, offering a broad CRO footprint across pharma discovery, in vivo, safety, and bioanalytical services. It competes with ProQinase through multiple subsidiaries, particularly in kinase profiling, safety assessment, and biomarker assays.

TypeBroad incumbent
Description

Charles River is a large preclinical CRO with end-to-end discovery, safety assessment, and in vivo pharmacology capabilities. Its Early Discovery and Safety Assessment segments overlap directly with ProQinase's biochemical, cell-based, in vivo, and GLP toxicology offerings, often competing for the same enterprise pharma programs at greater scale.

TypeBroad incumbent
Description

Labcorp (including its Covance legacy) offers preclinical and clinical CRO services spanning discovery biology, safety assessment, and bioanalytical/PK work. It competes with ProQinase in cell-based profiling, in vivo pharmacology, biomarker, and safety/toxicology service lines, typically at much larger scale.

TypeBroad incumbent
Description

Reaction Biology is the parent platform that operates ProQinase as a sub-brand. Reaction Biology's broader discovery-services catalog (biochemical, cell-based, biophysical, in vivo, safety) overlaps directly with ProQinase's offerings, while ProQinase contributes kinase and epigenetic specialty depth within the same corporate family.

TypeDirect peer
Description

Promega supplies kinase assay reagents, luminescent and fluorescent biochemical kits, and cell-based profiling tools that overlap with ProQinase's kinase and biochemical assay services. Both serve pharma and academic customers needing validated, reproducible enzyme and cell-based assay infrastructure.

TypeBroad incumbent
Description

Thermo Fisher's PPD CRO segment provides preclinical and clinical research services including discovery biology, bioanalytical, and safety assessment. It overlaps with ProQinase in biochemical and cell-based assay services and competes for global pharma R&D outsourcing budgets at significantly greater scale.

TypeDirect peer
Description

DiscoverX, now part of Eurofins, provides cell-based and biochemical assay platforms (e.g., PathHunter, KINOMEscan) for kinase, GPCR, and other drug target screening. It competes head-to-head with ProQinase's kinase panel screening, KinaseFinder tools, and cell-based profiling services.

TypeDirect peer
Description

Eurofins Discovery is a leading specialty CRO offering in vitro pharmacology, kinase profiling, cell-based assays, and in vivo services — directly mirroring ProQinase's preclinical drug discovery menu. Both compete for the same pharma and biotech discovery-program contracts across kinase, biophysical, and cell-based assay modalities.

TypeDirect peer
Description

Selvita is a contract research organization providing integrated drug discovery services including biochemical and cell-based assays, in vitro ADME, in vivo pharmacology, and medicinal chemistry. Its discovery-service portfolio is a strong direct comparator to ProQinase's preclinical offering.

10Carna Biosciences
TypeDirect peer
Description

Carna Biosciences is a kinase-focused Japanese CRO and reagent provider with biochemical kinase profiling, cell-based kinase assays, and a kinase inhibitor screening platform. Its product-and-service mix is the closest direct comparator to ProQinase's kinase specialty franchise.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

ProQinase

Preclinical Drug Discovery Servicesproqinase.com

ProQinase is a Germany-based preclinical drug discovery CRO operating under Reaction Biology, providing kinase profiling, epigenetic, cell-based, biophysical, and in vivo pharmacology services to pharmaceutical, biotech, and academic clients across US and EU facilities.

What ProQinase does

ProQinase is a contract research organization (CRO) specializing in preclinical drug discovery services with a primary focus on kinase profiling and epigenetic target screening. Founded in 2001 and headquartered in Freiburg, Germany, the company operates under the Reaction Biology legal entity with facilities in the European Union and the United States. Its service portfolio spans biochemical assays (kinase panels, methyltransferase, HDAC, HAT, demethylase, GPCR, ion channel, phosphatase), cell-based assays (ProLiFiler cancer cell panel, 3D tumor spheroids, immune checkpoint, CAR-T), biophysical assays (SPR, MST, ITC, TSA), in vivo pharmacology (xenograft, orthotopic, PK/PD), safety/toxicology, GMP bioassays, and custom assay development. Proprietary platforms include LinkLight (protein-protein interaction analysis), ProLiFiler (cancer cell panel screening), and SubQperior (tumor models), supported by a library of hundreds of validated proteins and over 1,000 cell lines.

The company serves pharmaceutical companies, biotechnology firms, and academic research institutions, with named relationships including Boehringer-Ingelheim, Perha Pharmaceuticals, ManRos Therapeutics, the University of North Carolina at Chapel Hill, and Ludwig-Maximilian's University of Munich. Revenue is generated primarily through project-based contract research services and the sale of recombinant kinase proteins and assay reagents, with pricing structured on a quote-per-project basis typical of enterprise CRO engagements. Recent product expansion covers emerging modalities including Antibody Drug Conjugates, RAS drug discovery, Targeted Protein Degradation, and EGFR programs, alongside an immuno-oncology service line and entry into the Chinese market via a localized website. Leadership is provided by CEO Sebastian Dempe and founder Christoph Schächtele, who has been involved since the company's inception.

ProQinase firmographics

Firmographics
Name
ProQinase
Legal name
Reaction Biology
Website
https://proqinase.com
Company type
Private
Founded year
2001
Operating status
Operating
Headcount range
1–10 employees
Short description
ProQinase is a Germany-based preclinical drug discovery CRO operating under Reaction Biology, providing kinase profiling, epigenetic, cell-based, biophysical, and in vivo pharmacology services to pharmaceutical, biotech, and academic clients across US and EU facilities.
Ownership category
akta.pro rank

ProQinase industry classification

Industry
Product category
Preclinical Drug Discovery Services
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAAAB
Preclinical CROs (Discovery/Pharmacology/DMPK)
SECONDARYHLAGAAAD
Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity)
SECONDARYHLAGAFAC
DMPK / ADME & Bioanalysis
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Preclinical drug discovery
  • Kinase assay services
  • Contract research organization
  • Recombinant kinase proteins
  • Epigenetic drug discovery

Where ProQinase is headquartered

Location

Headquarters

HQ city
Freiburg
HQ country
Germany
HQ region
Europe

Offices2 records

Markets served

ProQinase business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

  1. Contract Research Services: CRO services providing preclinical drug discovery including biochemical assays, cell-based assays, biophysical assays, safety & toxicology, in vivo pharmacology, and custom assay development for pharmaceutical, biotech, and academic clients
  2. Recombinant Protein Products: Sale of kinase proteins, epigenetic proteins, and related assay reagents including active protein kinases, lipid kinases, methyltransferase proteins, deacetylase proteins, and assay kits

Pricing tiers

ModelBillingPrice
OtherMulti-year contractCustom CRO project-based pricing

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

ProQinase product offering

Product offering

Core offering

ProQinase, operating as the kinase services brand of Reaction Biology, is a contract research organization (CRO) providing preclinical drug discovery services. Core offerings include kinase panel screening, biochemical and cell-based assays, biophysical assays (SPR, MST, ITC, TSA), in vivo pharmacology, immuno-oncology platforms, recombinant kinase proteins, and safety/toxicology testing for pharmaceutical, biotech, and academic clients.

Product overview

ProQinase (now part of Reaction Biology) offers an integrated drug discovery service portfolio. The core offerings include kinase panel screening services and recombinant kinase products (Active Protein Kinases, Active Lipid Kinases), supplemented by epigenetic assay services (Methyltransferase, Demethylase, HDAC, HAT, Reader Domain assays). The platform includes discovery tools (KinaseFinder, Kinase SubstrateFinder, Kinase Mapper, MoA Finder, Biomarker Analysis Tool) for target identification and compound profiling. Additional services span biophysical assays (SPR, MST, ITC, TSA), cell-based assays (ProLiFiler Cancer Cell Panel, 3D Tumor Spheroid), in vivo pharmacology models, immuno-oncology platforms (CAR-T), GMP bioassays, safety/toxicology screening, and custom drug discovery services. The product line also includes assay kits (BromoMELT Assay Kit) and reagent products. The company operates from strategically located facilities in the US and EU with over 1,000 cell lines and hundreds of validated protein targets.

Differentiator

Problem solved

Functional benefit

Products and services

  • Kinase Panel Screening Comprehensive screening of kinases across the kinome to identify target engagement and selectivity profiles for pharmaceutical, biotech, and academic clients.
  • Kinase Assay Services Individual kinase assay services providing quantitative measurement of kinase activity and inhibition for drug discovery clients.
  • Epigenetic Assay Services Biochemical assays for profiling methyltransferase, demethylase, histone acetyltransferase (HAT), histone deacetylase (HDAC), sirtuin, and reader domain activity for epigenetic drug discovery.
  • Biophysical Assay Services Biophysical assays including Surface Plasmon Resonance (SPR), Thermal Shift Assay (TSA), Microscale Thermophoresis (MST), and Isothermal Titration Calorimetry (ITC) for measuring molecular interactions and binding kinetics.
  • ProLiFiler Cancer Cell Panel Screening Proprietary cancer cell line panel screening service for phenotypic profiling of compound efficacy across a panel of cancer cell lines.
  • 3D Tumor Spheroid Assay Three-dimensional cell culture assay using tumor spheroids for physiologically relevant drug efficacy testing in oncology drug discovery.
  • CAR-T Cell Therapy Platform Platform for evaluating CAR-T cell therapeutic candidates and immune responses in immuno-oncology drug discovery.
  • In Vivo Pharmacology Preclinical in vivo efficacy models including xenograft tumor models, PK/PD studies, and translational pharmacology for drug discovery programs.
  • GMP Bioassays Regulatory-compliant bioanalytical testing and quality control services for bioprocessing and biotherapeutic manufacturing.
  • Safety & Toxicology Services Comprehensive safety profiling including in vitro safety screening, cardiac safety assessment, cytochrome P450 assays, and GLP toxicology for drug development programs.
  • Custom Drug Discovery Services Customized kinase and epigenetic drug discovery services tailored to specific client research needs, including custom assay development and cell line generation.
  • Active Protein Kinases Recombinant active protein kinases sold as standalone reagents for use in biochemical screening and profiling assays.
  • Active Lipid Kinases Recombinant lipid kinases sold as standalone reagents for lipid kinase inhibitor screening and research.
  • BromoMELT Assay Kit Assay kit for measuring bromodomain binding and ligand-induced thermal stability, sold as a standalone reagent product.

Quantifiable outcome

  • Therapies developed using company services have received regulatory approval from FDA and other global regulatory agencies

Companies that use ProQinase

Customer profile

Named customers4 records

Segments3 records

Ideal customer profiles3 records

ProQinase technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

ProQinase partnerships and signals

Strategic signal

Scale indicators4 records

Recent moves1 record

Expansion highlights5 records

ProQinase competitors and assessment

Company assessment

Broad incumbents

  • Eurofins Scientific: Eurofins Scientific is the parent of Eurofins Discovery and DiscoverX, offering a broad CRO footprint across pharma discovery, in vivo, safety, and bioanalytical services. It competes with ProQinase through multiple subsidiaries, particularly in kinase profiling, safety assessment, and biomarker assays.
  • Charles River Laboratories: Charles River is a large preclinical CRO with end-to-end discovery, safety assessment, and in vivo pharmacology capabilities. Its Early Discovery and Safety Assessment segments overlap directly with ProQinase's biochemical, cell-based, in vivo, and GLP toxicology offerings, often competing for the same enterprise pharma programs at greater scale.
  • Labcorp Drug Development: Labcorp (including its Covance legacy) offers preclinical and clinical CRO services spanning discovery biology, safety assessment, and bioanalytical/PK work. It competes with ProQinase in cell-based profiling, in vivo pharmacology, biomarker, and safety/toxicology service lines, typically at much larger scale.
  • Reaction Biology Corporation: Reaction Biology is the parent platform that operates ProQinase as a sub-brand. Reaction Biology's broader discovery-services catalog (biochemical, cell-based, biophysical, in vivo, safety) overlaps directly with ProQinase's offerings, while ProQinase contributes kinase and epigenetic specialty depth within the same corporate family.
  • Thermo Fisher Scientific (PPD): Thermo Fisher's PPD CRO segment provides preclinical and clinical research services including discovery biology, bioanalytical, and safety assessment. It overlaps with ProQinase in biochemical and cell-based assay services and competes for global pharma R&D outsourcing budgets at significantly greater scale.

Direct peers

  • Promega Corporation: Promega supplies kinase assay reagents, luminescent and fluorescent biochemical kits, and cell-based profiling tools that overlap with ProQinase's kinase and biochemical assay services. Both serve pharma and academic customers needing validated, reproducible enzyme and cell-based assay infrastructure.
  • DiscoverX (Eurofins): DiscoverX, now part of Eurofins, provides cell-based and biochemical assay platforms (e.g., PathHunter, KINOMEscan) for kinase, GPCR, and other drug target screening. It competes head-to-head with ProQinase's kinase panel screening, KinaseFinder tools, and cell-based profiling services.
  • Eurofins Discovery: Eurofins Discovery is a leading specialty CRO offering in vitro pharmacology, kinase profiling, cell-based assays, and in vivo services — directly mirroring ProQinase's preclinical drug discovery menu. Both compete for the same pharma and biotech discovery-program contracts across kinase, biophysical, and cell-based assay modalities.
  • Selvita: Selvita is a contract research organization providing integrated drug discovery services including biochemical and cell-based assays, in vitro ADME, in vivo pharmacology, and medicinal chemistry. Its discovery-service portfolio is a strong direct comparator to ProQinase's preclinical offering.
  • Carna Biosciences: Carna Biosciences is a kinase-focused Japanese CRO and reagent provider with biochemical kinase profiling, cell-based kinase assays, and a kinase inhibitor screening platform. Its product-and-service mix is the closest direct comparator to ProQinase's kinase specialty franchise.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

ProQinase social profiles

Digital presence

ProQinase financial estimates

Financial estimate

Revenue estimate

Valuation estimate

ProQinase leadership team

Management profile

Number of profiles

Profiles2 records

ProQinase funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

ProQinase M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ProQinase

What does ProQinase do?

ProQinase, operating as the kinase services brand of Reaction Biology, is a contract research organization (CRO) providing preclinical drug discovery services. Core offerings include kinase panel screening, biochemical and cell-based assays, biophysical assays (SPR, MST, ITC, TSA), in vivo pharmacology, immuno-oncology platforms, recombinant kinase proteins, and safety/toxicology testing for pharmaceutical, biotech, and academic clients.

When was ProQinase founded?

ProQinase was founded in 2001. It employs 1 to 10 people.

Where is ProQinase based?

ProQinase is headquartered in Freiburg, Germany, in the Europe region.

How does ProQinase make money?

Two revenue lines are on record. Contract Research Services are the primary driver. The others are recombinant Protein Products.

Who are ProQinase's main competitors?

Broad incumbents on record are Eurofins Scientific, Charles River Laboratories, Labcorp Drug Development, Reaction Biology Corporation and Thermo Fisher Scientific (PPD). Direct peers are Promega Corporation, DiscoverX (Eurofins), Eurofins Discovery, Selvita and Carna Biosciences.

Does ProQinase have an API?

No public API is recorded for ProQinase.

What industry is ProQinase in?

ProQinase's product category is Preclinical Drug Discovery Services. Its primary akta.pro industry code is HLAGAAAB, Preclinical CROs (Discovery/Pharmacology/DMPK), with a secondary code of HLAGAAAD, Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireOB-002 Significantly Reduces Bone Metastasis in a Murine Model of Breast CancerOrion Biotechnology Canada announced that its drug candidate OB-002 significantly reduced bone metastasis in a preclinical murine model of breast cancer, with mice receiving 80 mg/kg demonstrating significant reduction in spinal bone metastasis compared to placebo. The study, conducted in collaboration with ProQinase in Heidelberg, Germany, showed that the CCR5 receptor antagonist also reduced primary tumor volume at both 20 mg/kg and 80 mg/kg doses. The company indicated these preliminary preclinical data suggest OB-002 has potential as a treatment for breast cancer-associated bone metastasis, which affects approximately 70% of women who die from breast cancer.PR NewswireReaction Biology Corporation adquiere ProQinase GmbHReaction Biology Corporation (RBC) completed a stock-for-share exchange transaction to acquire all shares of ProQinase GmbH, an early-stage drug discovery company based in Freiburg, Germany, founded in 2001. As part of the deal, ChinaEquity Group became RBC's majority shareholder, providing strategic backing for the combined entity's planned expansion into China. The merger creates the first international kinase-associated drug discovery company with combined operations across Europe and the United States, serving a client base of approximately 1,500 customers.PR NewswireReaction Biology Corporation erwirbt ProQinase GmbHReaction Biology Corporation (RBC) completed a stock swap transaction with ChinaEquity Group to acquire all shares of ProQinase GmbH, an early-stage kinase-based drug discovery company headquartered in Freiburg, Germany. The merger creates a globally leading kinase drug discovery company serving nearly 1,500 combined customers with operations across Europe and the United States. RBC also announced plans to open a subsidiary in China in partnership with ChinaEquity Group, which became RBC's major shareholder through this transaction.PR NewswireReaction Biology Corporation acquiert ProQinase GmbHReaction Biology Corporation completed the acquisition of ProQinase GmbH, a drug discovery company based in Germany. Concurrently, ChinaEquity Group became the principal shareholder of Reaction Biology through a share exchange transaction. This combination creates a multinational drug discovery platform with operations spanning Europe, the United States, and China.PR NewswireReaction Biology Corporation Purchases ProQinase GmbHReaction Biology Corporation (RBC) has completed a stock swap transaction to acquire all shares of ProQinase GmbH from ChinaEquity Group, combining two early-stage drug-discovery companies. The merger creates the world's leading kinase drug-discovery company with nearly 1,500 combined customers, operations spanning Europe and the United States, and plans for a China-based subsidiary. RBC and ProQinase plan to continue expanding operations and product offerings from their respective facilities in Pennsylvania and Freiburg, Germany.